ArticleEJHaem2026
Recognizing Hemophagocytic Lymphohistiocytosis (HLH) in an Urban Population: Clinical Characteristics, Treatment Patterns, and Outcomes.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome with high mortality in adults. Diagnosis remains challenging due to nonspecific clinical features and overlap with sepsis, malignancy, and other inflammatory conditions. Data on HLH in underserved populations are limited. Methods: We performed a retrospective cohort study of adult patients at a single urban tertiary care center from 2019-2025. Patients were identified using ICD-10 codes for HLH and/or ferritin > 6000 ng/mL. Hscores and HLH-2004 criteria were calculated to identify high-probability cases. Patients were stratified into those diagnosed with HLH during hospitalization (Cohort 1) and those meeting criteria retrospectively without clinical recognition (Cohort 2). Results: Among 273 patients screened, 68 were identified as high-probability of HLH, defined as an Hscore > 169 and/or fulfillment of at least five HLH-2004 diagnostic criteria. Twenty-five patients met inclusion criteria after secondary review. Seventeen patients were included in Cohort 1 and eight in Cohort 2. Cohort 1 patients were younger (median age 34 vs. 62 years) and predominantly Black or Hispanic, with high rates of uninsured status and social vulnerability. HIV (42.1%), infection (29.4%), and malignancy (17.6%) were the most common triggers. HLH-directed therapy was administered in 82% of Cohort 1; mortality was 52.9%. In contrast, Cohort 2 patients demonstrated similar laboratory features but were not clinically recognized, with a high mortality rate of 87.57%. Hematology consultation occurred in 100% of Cohort 1 compared to 62.5% of Cohort 2. Conclusion: HLH is associated with high mortality and may be underrecognized in complex hospitalized patients, particularly older individuals with competing diagnoses. Early use of diagnostic tools such as the Hscore and prompt hematology consultation may improve recognition and outcomes, especially in high-risk populations including those with HIV, malignancy, or severe infection. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.